Chlamydia Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention
Jan 18, 2018
Chlamydia
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chlamydia — Rates: United States, 1984–2004
Rate (per 100,000 population)
0
70
140
210
280
350
1984 86 88 90 92 94 96 98 2000 02 04
Note: As of January 2000, all 50 states and the District of Columbia had regulations requiring the reporting of chlamydia cases.
Chlamydia — Rates by state: United States and outlying areas, 2004
Note: The total rate of chlamydia for the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 316.7 per 100,000 population.
Rate per 100,000population
<=150.0150.1-300.0>300.0
VT 183.6 NH 134.8 MA 205.8 RI 319.8 CT 274.2 NJ 202.0 DE 361.3 MD 362.2
Guam 457.2
Puerto Rico 92.5 Virgin Is. 278.5
(n= 2)(n= 25)(n= 26)
295.8
609.4
300.8288.5
344.4 311.0
250.0
394.7
422.0
203.8
372.9 297.6
236.3
275.1157.1
485.7
161.8
409.2
229.3
654.7
373.7
284.2
301.2298.5
482.0
308.0
344.5
285.6
344.3
295.2
244.1
307.5
444.2
331.3
385.4
317.5
164.0
292.9
287.6
152.3
351.2
215.9
Chlamydia — Rates by county: United States, 2004
Rate per 100,000population
<=150.0 (n= 1,415)
150.1-300.0 (n= 985)
>300.0 (n= 739)
Chlamydia — Rates by region: United States, 1984–2004
Rate (per 100,000 population)
WestMidwestNortheastSouth
0
70
140
210
280
350
1984 86 88 90 92 94 96 98 2000 02 04
Chlamydia — Rates by sex: United States, 1984–2004
Rate (per 100,000 population)
MenWomen
0
100
200
300
400
500
1984 86 88 90 92 94 96 98 2000 02 04
Chlamydia — Age- and sex-specific rates: United States, 2004
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14 10.8
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
458.3
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
744.7
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
402.9
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
185.2
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
99.3
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
56.1
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
23.0
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
7.4
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2.2
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
147.5
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14 132.0
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2,761.5
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2,630.7
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1,039.5
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
364.8
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
148.3
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
62.6
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
22.4
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
6.2
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2.0
Men Rate (per 100,000 population) Women
Age3,000 2,400 1,800 1,200 600 0 0 600 1,200 1,800 2,400 3,000
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
486.2
Chlamydia — Positivity among 15- to 24-year-old women tested in family planning clinics by state: United States and outlying areas, 2004
Note: Includes states and outlying areas that reported chlamydia positivity data on at least 500 women aged 15-24 years screened during 2004.
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention
Positivity (%)
<4.04.0-4.9>=5.0
VT 4.0 NH 4.0 MA 5.4 RI 6.4 CT 5.1 NJ 7.8 DE 6.5 MD 6.1 DC 3.9
Puerto Rico 5.9 Virgin Is. 14.9
(n= 3)(n= 10)(n= 40)
6.9
4.7
7.2 6.1
6.3 6.4
4.9
9.5
8.7
4.6
7.2 7.7
4.9
5.7 4.1
9.0
4.1
7.4
7.1
16.3
7.2
6.1
4.9 3.9
9.5
6.0
7.3
5.9
7.6
5.6
4.3
6.1
11.8
5.7
6.6
8.6
9.3
7.5
7.1
3.2
8.5
5.4
Chlamydia — Trends in positivity among 15- to 24-year-old women tested in family planning clinics by HHS region, 1988–2004
Note: Annual positivity adjusted for changes in laboratory test method and associated increases in test sensitivity.
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers for Disease Control and Prevention
Region I
Region II
Region III
Region IV
Region V
Region VIRegion VII
Region VIII
Region IX
Region X
9.0
96
6.0
97
5.9
98
5.2
99
6.2
00
6.4
01
6.1
02
5.5
03
5.4
04
7.8
97
8.8
98
8.3
99
8.6
00
9.8
01
9.1
02
10.2
03
9.7
04
10.1
94
8.1
95
7.3
96
7.7
97
8.0
98
8.4
99
7.9
00
7.2
01
6.8
02
6.9
03
7.5
04
11.2
97
12.7
98
11.7
99
10.5
00
10.4
01
10.1
02
9.6
03
10.9
04
7.5
97
10.2
98
9.2
99
8.8
00
8.0
01
8.2
02
8.7
03
8.8
04
12.6
96
12.8
97
13.6
98
12.0
99
12.0
00
11.5
01
11.8
02
11.7
03
11.7
04
6.1
96
5.8
97
6.3
98
6.1
99
6.3
00
6.1
01
6.5
02
6.5
03
6.8
04
7.6
94
6.5
95
6.2
96
5.9
97
6.6
98
6.7
99
6.6
00
7.1
01
7.4
02
7.3
03
7.6
04
7.0
96
7.6
97
8.1
98
9.3
99
8.7
00
8.8
01
8.0
02
8.5
03
8.5
04
15.1
88
11.8
89
11.4
90
9.5
91
8.2
92
6.1
93
5.7
94
5.1
95
4.9
96
4.9
97
5.6
98
6.0
99
6.1
00
6.2
01
6.7
02
7.5
03
7.7
04
IV
VIIIX
IIIX
III
VI
VVIII
GonorrheaSexually Transmitted Disease
Surveillance 2004
Division of STD Prevention
Gonorrhea — Rates: United States, 1970–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
Rate (per 100,000 population)
Gonorrhea2010 Target
0
100
200
300
400
500
1970 73 76 79 82 85 88 91 94 97 2000 03
Gonorrhea — Reported cases by reporting source: United States, 1984–2004
Note: Prior to 1996, the STD clinic source of report corresponded to public (clinic) source of report, and the non-STD clinic category corresponded to private source of report. After 1996, as states began reporting morbidity data electronically, the specific source of report (i.e., STD clinic) began to be reported from an increasing number of states.
Cases (in thousands)
non-STD ClinicSTD Clinic
0
150
300
450
600
750
1984 86 88 90 92 94 96 98 2001 02 04
Gonorrhea — Rates by state: United States and outlying areas, 2004
Note: The total rate of gonorrhea for the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 112.1 per 100,000 population. The Healthy People 2010 target is 19.0 cases per 100,000 population.
Rate per 100,000population
<=19.019.1-100.0>100.0
VT 13.9 NH 10.3 MA 47.5 RI 75.8 CT 82.2 NJ 77.5 DE 109.4 MD 150.6
Guam 69.7
Puerto Rico 6.9 Virgin Is. 68.9
(n= 8)(n= 25)(n= 20)
182.3
87.4
72.8151.8
85.0 67.1
109.2
181.7
94.9
7.5
162.8 110.6
42.4
93.367.0
234.4
16.1
172.4
58.4
248.6
161.6
9.6
65.9137.3
69.7
97.6
180.7
17.4
179.0
126.8
36.6
90.9
221.1
39.8
145.1
110.2
25.6
116.0
45.8
49.3
92.3
11.8
Gonorrhea — Rates by county: United States, 2004
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
Rate per 100,000population
<=19.0 (n= 1,330)
19.1-100.0 (n= 1,139)
>100.0 (n= 670)
Gonorrhea — Rates by region: United States, 1981–2004 and the HealthyPeople 2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
Rate (per 100,000 population)
WestMidwestNortheastSouth2010 Target
0
120
240
360
480
600
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Rates by sex: United States, 1981–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
Rate (per 100,000 population)
MaleFemale2010 Target
0
120
240
360
480
600
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Rates by race and ethnicity: United States, 1981–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for gonorrhea is 19.0 cases per 100,000 population.
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat2010 Target
0
500
1,000
1,500
2,000
2,500
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Age- and sex-specific rates: United States, 2004
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-145.8
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
252.9
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
430.6
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
302.1
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
178.6
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
124.5
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
89.6
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
48.1
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
17.0
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
4.1
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
110.2
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14 36.9
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
610.9
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
569.1
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
269.7
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
114.2
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
60.3
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
32.9
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
11.7
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2.5
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.6
Men Rate (per 100,000 population) Women
Age750 600 450 300 150 0 0 150 300 450 600 750
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
116.7
Gonorrhea — Age-specific rates among women 10 to 44 years of age:United States, 1981–2004
Rate (per 100,000 population)
10-1415-1920-2425-2930-3435-3940-44
0
300
600
900
1,200
1,500
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Age-specific rates among men 10 to 44 years of age:United States, 1981–2004
Rate (per 100,000 population)
10-1415-1920-2425-2930-3435-3940-44
0
400
800
1,200
1,600
2,000
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Positivity among 15- to 24-year-old women tested in family planning
clinics by state: United States and outlying areas, 2004
*States/areas reported gonorrhea positivity data on less than 500 women aged 15-24 years during 2004. Note: Includes states that reported gonorrhea positivity data on at least 500 women aged 15-24 years screened during 2004 except for Maine, which submitted gonorrhea positivity data for April-December 2004, and Minnesota which submitted gonorrhea positivity data for January-March and July-December 2004.
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers forDisease Control and Prevention
Positivity (%)
See*<1.01.0-1.9>=2.0
VT 0.3 NH 0.2 MA RI CT 0.6 NJ 1.5 DE MD DC 0.9
Puerto Rico 0.2 Virgin Is. 3.2
(n= 12)(n= 24)(n= 11)(n= 6)
1.1
0.1
1.4
1.0 0.3
0.5
2.1
0.9
1.4 0.9
0.4
0.7 0.6
2.0
0.1
1.8
0.9
3.0
1.0
0.7
0.4 0.9
1.0
0.5
1.7
0.72.0
0.8
1.3
0.8
1.1
0.3
4.2
0.2
Gonococcal Isolate Surveillance Project (GISP) — Location of participating clinics and regional laboratories: United States, 2004
STD ClinicsClinics and Regional Labs
Birmingham Phoenix
Long Beach Los Angeles
Orange Co. San Diego
San Francisco Denver
Miami
Atlanta
Honolulu Tripler AMC
Chicago
New Orleans
Baltimore
Detroit Minneapolis
St. Louis Las Vegas
Albuquerque Greensboro
Cincinnati
Cleveland
Oklahoma City
Portland
Philadelphia
Dallas
Seattle
Gonococcal Isolate Surveillance Project (GISP) — Penicillin and tetracycline resistance among GISP isolates, 2004
Note: PPNG=penicillinase-producing N. gonorrhoeae; TRNG=plasmid-mediated tetracycline-resistant N. gonorrhoeae; PPNG-TRNG=plasmid-mediated penicillin- and tetracycline-resistant N. gonorrhoeae; PenR=chromosomally mediated penicillin resistant N. gonorrhoeae; TetR=chromosomally mediated tetracycline-resistant N. gonorrhoeae; CMRNG=chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae.
SusceptiblePPNGTRNGPPNG/TRNGPenRTetRCMRNG
84.1%
0.6%
3.4%0.5%1.1%
6.1%
4.3%
Gonococcal Isolate Surveillance Project (GISP) — Percent of Neisseria gonorrhoeae isolates with resistance or intermediate resistance to ciprofloxacin,
1990–2004
Note: Resistant isolates have ciprofloxacin MICs ≥ 1 µg/ml. Isolates with intermediate resistance have ciprofloxacin MICs of 0.125 - 0.5 µg/ml. Susceptibility to ciprofloxacin was first measured in GISP in 1990.
Percent
ResistanceIntermediate resistance
0.0
2.0
4.0
6.0
8.0
10.0
1990 91 92 93 94 95 96 97 98 99 2000 01 02 03 04
Gonococcal Isolate Surveillance Project (GISP) — Percent of Neisseria gonorrhoeae isolates with resistance to ciprofloxacin by sexual behavior,
2001–2004
Percent Ciprofloxacin Resistant
HeterosexualMen who have sex with men (MSM)
0
5
10
15
20
25
2001 2002 2003 2004
SyphilisSexually Transmitted Disease
Surveillance 2004
Division of STD Prevention
Syphilis — Reported cases by stage of infection: United States, 1941–2004
Cases (in thousands)
P&SEarly LatentTotal Syphilis
0
120
240
360
480
600
1941 46 51 56 61 66 71 76 81 86 91 96 2001
Primary and secondary syphilis — Reported cases by reporting source:United States, 1984–2004
Cases (in thousands)
non-STD ClinicSTD Clinic
0
10
20
30
40
50
1984 86 88 90 92 94 96 98 2001 02 04
Note: Prior to 1996, the STD clinic source of report corresponded to public (clinic) source of report, and the non-STD clinic category corresponded to private source of report. After 1996, as states began reporting morbidity data electronically, the specific source of report (i.e., STD clinic) began to be reported from an increasing number of states.
Primary and secondary syphilis — Rates: United States, 1970–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
Rate (per 100,000 population)
P&S Syphilis2010 Target
0
5
10
15
20
25
1970 73 76 79 82 85 88 91 94 97 2000 03
Primary and secondary syphilis — Rates by state: United States and outlying areas, 2004
Note: The total rate of P&S syphilis for the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 2.8 per 100,000 population. The Healthy People 2010 target is 0.2 case per 100,000 population.
Rate per 100,000population
<=0.20.21-4.0>4.0
VT 0.2 NH 0.4 MA 1.8 RI 2.4 CT 1.3 NJ 1.7 DE 1.1 MD 6.9
Guam 0.0
Puerto Rico 4.7 Virgin Is. 4.6
(n= 7)(n= 39)(n= 7)
3.7
1.2
2.8 1.7
3.8 1.4
4.3
6.3
0.6
1.8
3.1 1.0
0.2
0.9 1.1
7.4
0.2
1.9
0.5
2.0
1.6
0.4
0.4 1.8
4.4
3.8
2.3
0.0
2.1
0.7
0.8
1.0
2.8
0.0
2.2
3.7
0.6
1.6
2.4
0.2
0.5
0.6
Primary and secondary syphilis — Rates by county: United States, 2004
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population. In 2004, 2,488 (79.3%) of 3,139 counties in the U.S. reported no cases of P&S syphilis.
Rate per 100,000population
<=0.2 (n= 2,493)
0.3-4.0 (n= 472)
>4.0 (n= 174)
Primary and secondary syphilis — Rates by region: United States, 1981–2004and the Healthy People 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
Rate (per 100,000 population)
WestMidwestNortheastSouth2010 Target
0
10
20
30
40
50
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Rates by sex: United States, 1981–2004and the Healthy People 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
Rate (per 100,000 population)
MaleFemale2010 Target
0
5
10
15
20
25
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Rates by race and ethnicity: United States,1981–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for P&S syphilis is 0.2 case per 100,000 population.
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat2010 Target
0
30
60
90
120
150
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Male-to-female rate ratios: United States, 1981–2004
Male-Female rate ratio
0
2:1
4:1
6:1
8:1
10:1
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Age- and sex-specific rates: United States, 2004
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-140.0
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.8
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
7.0
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
9.7
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
10.8
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
12.4
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
10.6
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
4.6
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.9
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.4
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
4.7
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14 0.1
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.5
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
3.0
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
2.0
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.6
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.5
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
1.3
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.6
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.2
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.0
Men Rate (per 100,000 population) Women
Age12.0 9.6 7.2 4.8 2.4 0.0 0.0 2.4 4.8 7.2 9.6 12.0
Total 65+55-6445-5440-4435-3930-3425-2920-2415-1910-14
0.9
Primary and secondary syphilis — Age-specific rates among women 10 to 44 years of age: United States, 1981–2004
Rate (per 100,000 population)
10-1415-1920-2425-2930-3435-3940-44
0
15
30
45
60
75
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Age-specific rates among men 10 to 44 yearsof age: United States, 1981–2004
Rate (per 100,000 population)
10-1415-1920-2425-2930-3435-3940-44
0
15
30
45
60
75
1981 83 85 87 89 91 93 95 97 99 2001 03
Congenital syphilis — Reported cases for infants <1 year of age and rates of primary and secondary syphilis among women: United States, 1970–2004
Note: The surveillance case definition for congenital syphilis changed in 1988.
Kaufman Criteria
CDC SurveillanceDefinition
P&S rate (per 100,000 population) CS cases (in thousands)
P&S Syphilis
CongenitalSyphilis
0
4
8
12
16
20
1970 75 80 85 90 95 20000.0
1.5
3.0
4.5
6.0
7.5
Congenital syphilis — Rates for infants <1 year of age: United States, 1981–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for congenital syphilis is 1.0 case per 100,000 livebirths. The surveillance case definition for congenital syphilis changed in 1988.
Rate (per 100,000 live births)
Cong. Syphilis2010 Target
0
25
50
75
100
125
1981 83 85 87 89 91 93 95 97 99 2001 03
Other SexuallyTransmitted Diseases
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chancroid — Reported cases: United States, 1981–2004
Cases (in thousands)
0
1
2
3
4
5
1981 83 85 87 89 91 93 95 97 99 2001 03
Genital herpes — Initial visits to physicians’ offices: United States, 1966–2004
Visits (in thousands)
0
60
120
180
240
300
1966 69 72 75 78 81 84 87 90 93 96 99 2002
Note: The relative standard error for these estimates range from 45% to 60%.SOURCE: National Disease and Therapeutic Index (IMS Health)
Genital warts — Initial visits to physicians’ offices: United States, 1966–2004
Note: The relative standard error for these estimates range from 40% to 60%.SOURCE: National Disease and Therapeutic Index (IMS Health)
Visits (in thousands)
0
80
160
240
320
400
1966 69 72 75 78 81 84 87 90 93 96 99 2002
Trichomoniasis and other vaginal infections in women — Initial visits to physicians’ offices: United States, 1966–2004
Note: The relative standard error for these estimates range from 16% to 30% and for othervaginitis estimates range from 30% to 60%.SOURCE: National Disease and Therapeutic Index (IMS Health)
Visits (in thousands)
TrichomoniasisOther Vaginitis
0
900
1,800
2,700
3,600
4,500
1966 69 72 75 78 81 84 87 90 93 96 99 2002
STDs in Women and Infants
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chlamydia — Rates among women by state: United States and outlying areas, 2004
Note: The total chlamydia infection rate among women in the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 480.7 per 100,000 female population.
Rate per 100,000population
<=300.0300.1-500.0>500.0
VT 273.3 NH 193.7 MA 294.3 RI 448.6 CT 412.0 NJ 326.8 DE 510.3 MD 566.5
Guam 759.0
Puerto Rico 160.9Virgin Is. 408.0
(n= 8)(n= 26)(n= 19)
503.3
851.9
462.3 449.2
497.6 455.9
396.5
628.8
640.9
316.5
558.6 451.5
348.1
451.1 239.4
758.4
229.0
636.2
334.1
1016.6
558.0
416.4
433.2 441.8
722.1
453.7
559.2
380.3
517.5
462.7
340.0
435.0
748.2
474.5
543.2
517.3
232.3
441.5
417.5
227.0
503.2
329.4
Gonorrhea — Rates among women by state: United States and outlying areas, 2004
Note: The total gonorrhea infection rate among women in the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 115.0 per 100,000 female population.
Rate per 100,000population
<=19.019.1-100.0>100.0
VT 16.8 NH 8.3 MA 46.1 RI 85.7 CT 98.0 NJ 81.3 DE 121.1 MD 152.2
Guam 87.4
Puerto Rico 7.4 Virgin Is. 84.4
(n= 7)(n= 22)(n= 24)
158.2
107.5
64.1146.0
76.6 73.4
107.9
184.6
108.4
6.2
178.6 112.7
49.2
114.0 67.4
235.5
12.6
187.5
67.1
293.7
175.9
11.7
74.5128.9
78.7
98.0
172.7
22.7
189.9
138.8
31.7
98.7
235.2
46.3
144.7
111.9
22.7
123.8
40.0
50.7
106.8
15.7
Primary and secondary syphilis — Rates for women by state: United States and outlying areas, 2004
Note: The total rate of P&S syphilis among women in the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 0.9 per 100,000 female population.
Rate per 100,000population
<=0.20.21-4.0>4.0
VT 0.0 NH 0.0 MA 0.2 RI 1.8 CT 0.2 NJ 0.9 DE 0.2 MD 3.2
Guam 0.0
Puerto Rico 3.1 Virgin Is. 5.3
(n= 20)(n= 31)(n= 2)
2.2
0.0
1.5 1.3
0.4 0.3
1.1
1.0
0.0
1.6
0.9 0.2
0.1
0.5 0.3
5.3
0.0
1.2
0.1
1.3
0.4
0.2
0.5 0.7
3.8
0.3
1.1
0.0
1.0
0.5
0.1
0.3
1.2
0.0
1.1
1.6
0.3
0.2
0.2
0.1
0.1
0.4
Congenital syphilis — Rates for infants <1 year of age by state: United States and outlying areas, 2004
Note: The total rate of congenital syphilis for infants < 1 year of age for the United States and outlying areas (Guam, Puerto Rico and Virgin Islands) was 8.9 per 100,000 live births. The Healthy People 2010 target is 1.0 case per 100,000 live births.
Rate per 100,000live births
<=1.01.1-10.0>10.0
VT 0.0 NH 0.0 MA 0.0 RI 7.8 CT 0.0 NJ 11.3 DE 9.0 MD 13.6
Guam 0.0
Puerto Rico 17.1 Virgin Is. 0.0
(n= 21)(n= 18)(n= 14)
18.7
0.0
29.6 10.7
12.1 2.9
7.8
3.8
0.0
14.3
12.7 4.7
0.0
5.1 1.8
27.7
0.0
17.7
1.5
7.2
2.7
0.0
0.00.0
10.8
7.2
7.7
0.0
1.3
4.0
0.0
0.0
16.5
0.0
5.2
17.5
2.0
6.0
0.0
0.0
0.0
0.0
Chlamydia — Positivity in 15- to 24-year-old women tested in prenatalclinics by state: United States and outlying areas, 2004
Positivity (%)
See*<5.05.0-9.9>=10.0
VT NH MA RI CT NJ 14.1 DE MD 3.1 DC
Puerto Rico 9.6 Virgin Is. 17.6
(n= 26)(n= 3)(n= 18)(n= 6)
7.7
7.8
5.3
8.6 5.8
6.3
5.9 5.4
12.2
14.6
6.0
5.9 5.3
6.7
7.4 5.9
3.1
10.9
10.4
6.8
9.3
9.5 3.7
*States not reporting chlamydia positivity data in prenatal clinics. Note: Includes states and outlying areas that reported chlamydia positivity data on at least 100 women aged 15-24 years during 2004 (except for Pennsylvania which submitted data for January-September 2004 only).
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers forDisease Control and Prevention
Gonorrhea — Positivity in 15- to 24-year-old women tested in prenatalclinics by state: United States and outlying areas, 2004
*States not reporting gonorrhea positivity data in prenatal clinics. Note: Includes states and outlying areas that reported gonorrhea positivity data on at least 100 women aged 15-24 years during 2004.
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers forDisease Control and Prevention
Positivity (%)
See*<1.01.0-1.9>=2.0
VT NH MA RI CT NJ DE MD DC
Puerto Rico 0.2 Virgin Is. 3.5
(n= 32)(n= 12)(n= 5)(n= 4)
1.2
1.2
0.7
1.1 0.8
0.0
0.9 0.7
2.7
3.1
0.3
0.50.0
0.2 0.4
2.4
1.1
0.9
1.3
Ectopic pregnancy — Hospitalizations of women 15 to 44 years of age: United States, 1980–2003
Hospitalizations (in thousands)
0
20
40
60
80
100
1980 82 84 86 88 90 92 94 96 98 2000 02
Note: Some variations in 1981 and 1988 estimates may be due to changes in sampling procedures. The relative standard error for these estimates ranges from 8% to 12%. Data available through 2003.
SOURCE: National Hospital Discharge Survey (National Center for Health Statistics, CDC)
Pelvic inflammatory disease — Hospitalizations of women 15 to 44 years of age: United States, 1980–2003
Note: The relative standard error for these estimates of the total number of acute and chronic PID cases ranges from 6% to 18%. Data available through 2003.
SOURCE: National Hospital Discharge Survey (National Center for Health Statistics, CDC)
Hospitalizations (in thousands)
Acute, Unspec.Chronic
0
40
80
120
160
200
1980 82 84 86 88 90 92 94 96 98 2000 02
Pelvic inflammatory disease — Initial visits to physicians’ offices by women 15 to 44 years of age: United States, 1980–2004
Note: The relative standard error for these estimates ranges from 19% to 30%.
Visits (in thousands)
0
100
200
300
400
500
1980 82 84 86 88 90 92 94 96 98 2000 02 04
SOURCE: National Disease and Therapeutic Index (IMS Health)
STDs in Adolescents and Young Adults
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chlamydia — Trends in positivity among 15- to 19-year-old women tested in family planning clinics by HHS regions, 1988–2004
Note: Trends adjusted for changes in laboratory test method and associated increases in test sensitivity. No data on laboratory test method available for Region VII in 1995 and Regions IV and V in 1996.
SOURCE: Regional Infertility Prevention Projects; Office of Population Affairs; Local and State STD Control Programs; Centers forDisease Control and Prevention
Region I
Region II
Region III
Region IV
Region V
Region VIRegion VII
Region VIII
Region IX
Region X
10.3
96
7.3
97
6.9
98
6.2
99
7.0
00
7.3
01
6.5
02
5.9
03
5.7
04
10.5
97
11.7
98
10.1
99
11.0
00
12.4
01
11.7
02
12.9
03
12.5
04
12.8
94
10.3
95
9.1
96
9.4
97
9.7
98
10.1
99
9.4
00
8.7
01
8.3
02
8.3
03
9.1
04
13.8
97
14.9
98
13.5
99
12.4
00
12.3
01
12.2
02
11.8
03
13.0
04
9.5
97
12.1
98
10.9
99
10.2
00
9.2
01
9.4
02
9.9
03
10.1
04
15.5
96
15.7
97
16.2
98
14.4
99
14.2
00
13.9
01
14.4
02
13.9
03
14.1
04
7.7
96
7.1
97
7.4
98
7.2
99
7.5
00
7.2
01
7.5
02
7.3
03
7.9
04
9.0
94
7.4
95
7.0
96
6.5
97
7.2
98
7.3
99
6.9
00
8.0
01
8.4
02
7.8
03
7.8
04
8.2
96
9.7
97
10.0
98
10.6
99
10.4
00
10.3
01
9.0
02
9.5
03
10.0
04
17.8
88
14.4
89
13.5
90
11.7
91
10.2
92
7.7
93
7.0
94
5.8
95
5.8
96
5.7
97
6.4
98
6.8
99
6.9
00
7.1
01
7.6
02
8.7
03
9.0
04
IV
VIIIX
IIIX
III
VI
VVIII
Chlamydia — Positivity among women tested in family planning clinics byage group: Region X, 1988–2004
Percent
<18 Years18-19 Years20-24 Years25-29 Years30+ Years
0
3
6
9
12
15
1988 90 92 94 96 98 2000 02 04
Note: Women who met screening criteria were tested. Trends not adjusted for changes in laboratory test method and associated increases in test sensitivity in 1994 and 1999–2004.
SOURCE: Regional Infertility Prevention Projects: Region X Chlamydia Project
Chlamydia — Prevalence among 16- to 24-year-old women entering the National Job Training Program by state of residence: United States and outlying areas, 2004
*Fewer than 100 women residing in these states/areas and entering the National Job Training Program were screened for chlamydia in 2004. Note: The overall chlamydia prevalence among female students entering theNational Job Training Program in 2004 was 10.3%.
Prevalence (%)
See*<10.010.0-14.9>=15.0
VT 4.4 NH MA 9.4 RI CT 10.8 NJ DE MD 13.7 DC
Puerto Rico 9.4 Virgin Is.
(n= 14)(n= 22)(n= 16)(n= 1)
17.3
13.2 11.2
8.2
11.2
10.0
10.6
6.5
14.1 9.5
11.5 8.1
14.3
9.7
11.9
14.3
10.1
5.1
5.5 9.7
7.7
9.2
5.3
12.8
9.0
4.6
9.3
9.1
6.5
14.3
7.3
13.7
8.2
9.8
Chlamydia — Prevalence among 16- to 24-year-old men entering the National Job Training Program by state of residence: United States and outlying areas, 2004
*Fewer than 100 men residing in these states/areas and entering the National Job Training Program were screened for chlamydia in 2004. Note: The overall chlamydia prevalence among male students entering theNational Job Training Program in 2004 was 8.3%.
Prevalence (%)
See*<10.010.0-14.9>=15.0
VT 1.6 NH MA 4.7 RI CT 6.4 NJ 8.1 DE MD 10.4 DC 9.9
Puerto Rico 6.0 Virgin Is.
(n= 5)(n= 36)(n= 12)
12.8
6.9
5.7 9.2
4.6 5.1
8.3
13.0
5.5
3.7
8.9 10.7
2.8
7.7 9.7
12.2
0.8
10.9
5.4
11.2
8.1
4.1
6.7 6.3
6.3
8.5
9.8
2.3
12.7
8.9
2.6
6.7
10.4
3.3
12.5
10.5
3.4
11.7
4.5
7.8
5.8
Gonorrhea — Prevalence among 16- to 24-year-old women entering the National Job Training Program by state of residence: United States and outlying areas, 2004
*Fewer than 100 women residing in these states/areas and entering the National Job Training Program werescreened for gonorrhea by the national contract laboratory in 2004. Note: Many training centers test female students for gonorrhea using local laboratories; these results are not available to CDC. For this map, gonorrhea test results for students at centers submitting specimens to the national contract laboratory were included if the number of gonorrhea tests submitted was greater than 90% of the number of chlamydia tests submitted. The overall gonorrhea prevalence among female students entering the National Job Training Program in 2004 was 2.5%.
Prevalence (%)
See*<2.02.0-4.9>=5.0
VT 0.6 NH MA 2.2 RI CT 2.9 NJ DE MD 1.9 DC
Puerto Rico Virgin Is.
(n= 20)(n= 13)(n= 19)(n= 1)
3.8
1.6
1.4
2.8
3.6
1.4
1.0
4.3 2.4
3.1
4.0
3.6
0.9
3.0
3.2
0.0
1.8
1.3
3.1
0.7
6.4
2.6
0.9
1.8
4.3
2.7
2.2
3.6 2.3
Prevalence (%)
Puerto Rico 0.4
Virgin Is.
See*
<2.0
2.0-4.9
>=5.0
(n= 29)
(n= 21)
(n= 3)
VTNHMARICT 1.6NJ 0.6DEMDDC0.7
0.3
1.7
0.0
1.5
1.9
1.7
0.0
2.0
2.1
1.8
0.40.2
1.4
2.3
0.4
1.1
0.0
1.4
1.20.0
Gonorrhea — Prevalence among 16- to 24-year-old men entering the National Job Training Program by state of residence: United States and outlying areas, 2004
*Fewer than 100 men residing in these states/areas and entering the National Job Training Program werescreened for gonorrhea by the national contract laboratory in 2004. Note: Many training centers test male students for gonorrhea using local laboratories; these results are not available to CDC. For this map, gonorrhea test results for students at centers submitting specimens to the national contract laboratory were included if the number of gonorrhea tests submitted was greater than 90% of the number of chlamydia tests submitted. The overall gonorrhea prevalence among male students entering the National JobTraining Program in 2004 was 3.1%.
STDs in Racial and Ethnic Minorities
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chlamydia — Positivity among women tested in family planning clinics by race and ethnicity: Region X, 1988–2004
Percent
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat
0
3
6
9
12
15
1988 90 92 94 96 98 2000 02 04
Note: Women who met screening criteria were tested. Annual race/ethnicity-specific positivity not adjusted for changes in laboratory test method and associated increases in test sensitivity in 1994, and 1999–2004.
SOURCE: Regional Infertility Prevention Projects: Region X Chlamydia Project
Gonorrhea — Rates by race/ethnicity and sex, 2004
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White26.2
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
670.3
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
64.9
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
19.4
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
79.0
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
110.2
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White 40.0
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
592.5
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
78.2
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
23.2
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
155.3
Men Rate (per 100,000 population) Women
Race750 600 450 300 150 0 0 150 300 450 600 750
Total
AI/AN
Asian/PI
Hispanic
Black
White
116.7
Gonorrhea — Rates among 15- to 19-year-old females by race and ethnicity:United States, 1981–2004
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat
0
1,400
2,800
4,200
5,600
7,000
1981 83 85 87 89 91 93 95 97 99 2001 03
Gonorrhea — Rates among 15- to 19-year-old males by race and ethnicity:United States, 1981–2004
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat
0
1,400
2,800
4,200
5,600
7,000
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Rates by race/ethnicity and sex: United States, 2004
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White3.1
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
14.1
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
5.5
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
2.3
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
3.5
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
4.7
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White 0.3
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
4.3
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
0.7
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
0.2
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
2.9
Men Rate (per 100,000 population) Women
Race15.0 12.0 9.0 6.0 3.0 0.0 0.0 3.0 6.0 9.0 12.0 15.0
Total
AI/AN
Asian/PI
Hispanic
Black
White
0.8
Primary and secondary syphilis — Rates among 15- to 19-year-old females by race and ethnicity: United States, 1981–2004
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat
0
50
100
150
200
250
1981 83 85 87 89 91 93 95 97 99 2001 03
Primary and secondary syphilis — Rates among 15- to 19-year-old males by race and ethnicity: United States, 1981–2004
Rate (per 100,000 population)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat
0
25
50
75
100
125
1981 83 85 87 89 91 93 95 97 99 2001 03
Congenital syphilis — Rates among infants <1 year of age by mother’s race and ethnicity: United States, 1991–2004 and the Healthy People 2010 target
Note: The Healthy People 2010 target for congenital syphilis is 1.0 case per 100,000 live births. Less than 5% of cases had missing race/ethnicity information and were excluded.
Rate (per 100,000 live births)
WhiteBlackHispanicAsian/Pac IslAm Ind/AK Nat2010 Target
0
90
180
270
360
450
1991 92 93 94 95 96 97 98 99 2000 01 02 03 04
STDs in Men Who Have Sex with Men
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
MSM Prevalence Monitoring Project — Syphilis serologic reactivity among men who have sex with men, STD clinics, 1999–2004
*Data not reported in 2004.
7.4
2000
15.8
2001
10.4
2002
14.0
2003
3.7
1999
3.2
2000
7.1
2001
8.9
2002
10.4
2003
10.8
2004
4.1
1999
3.9
2000
3.5
2001
3.6
2002
5.5
2003
7.0
2004
1.5
2000
1.5
2001
3.7
2002
4.7
2003
5.7
2004
6.7
2001
10.3
2002
16.6
2003
14.0
2004
3.5
2000
4.3
2001
7.0
2002
8.5
2003
9.7
2004
3.4
2000
4.4
2001
5.9
2002
6.9
2003
9.5
2004
13.1
1999
6.9
2000
8.7
2001
12.1
2002
13.4
2003
13.0
2004
10.3
2002
10.2
2003
10.6
2004
Seattle, WA
San Francisco, CA
Long Beach, CA*
Denver, CO Houston, TX Chicago, IL
District of Columbia
Philadelphia, PA
New York City, NY
MSM Prevalence Monitoring Project — Gonorrhea positivity* among men who have sex with men, STD clinics, 1999–2004
*Includes testing at all anatomic sites.†Data not reported in 2004.
10.6
2000
16.9
2001
15.5
2002
16.9
2003
13.0
1999
18.4
2000
17.7
2001
16.7
2002
14.3
2003
15.6
2004
16.5
1999
11.7
2000
13.3
2001
19.2
2002
15.3
2003
15.4
2004
14.2
2000
13.6
2001
18.0
2002
13.0
2003
11.9
2004
19.3
2001
22.8
2002
17.5
2003
13.2
2004
22.4
2000
19.0
2001
12.5
2002
14.0
2003
11.4
2004
12.4
2000
10.7
2001
11.6
2002
10.1
2003
13.7
1999
18.9
2000
20.7
2001
17.8
2002
18.2
2003
17.3
2004
15.9
2002
19.5
2003
15.8
2004
Seattle, WA
San Francisco, CA
Long Beach, CA†
Denver, CO Houston, TX Chicago, IL
District of Columbia†
Philadelphia, PA
New York City, NY
MSM Prevalence Monitoring Project — Test positivity for gonorrhea, chlamydia, and HIV among men who have sex with men, by race/ethnicity, STD clinics, 2004
*Excludes persons previously known to be HIV-positive.
Median positivity
WhiteBlackHispanic
0
5
10
15
20
25
Urethralgonorrhea
Rectalgonorrhea
Pharyngealgonorrhea
Urethralchlamydia
HIV*
MSM Prevalence Monitoring Project —Positivity for gonorrhea and chlamydia among men who have sex with men, by HIV status, STD clinics, 2004
Median positivity
HIV-positiveHIV-negative or unknown
0
5
10
15
20
25
Urethralgonorrhea
Rectalgonorrhea
Pharyngealgonorrhea
Urethralchlamydia
Gonococcal Isolate Surveillance Project (GISP) — Percent of urethral Neisseria gonorrhoeae isolates obtained from men who have sex with men attending STD
clinics, 1988–2004
Percent
0
5
10
15
20
25
1988 90 92 94 96 98 2000 02 04
Gonococcal Isolate Surveillance Project (GISP) — Percent of Neisseria gonorrhoeae isolates obtained from men who have sex with men attending
STD clinics, 2001–2004
Note: Not all clinics participated in GISP for the last 4 years. Clinics include: ALB=Albuquerque, NM; ATL=Atlanta, GA; BAL=Baltimore, MD; BHM=Birmingham, AL; CHI=Chicago, IL; CIN=Cincinnati, OH; CLE=Cleveland, OH; DAL=Dallas, TX; DEN=Denver, CO; DTR=Detroit, MI; HON=Honolulu, HI; LAX=Los Angeles, CA; LBC=Long Beach, CA; LVG=Las Vegas, NV; MIA=Miami, FL; MIN=Minneapolis, MN; GRB=Greensboro, NC; NOR=New Orleans, LA; OKC=Oklahoma City, OK; ORA=Orange County, CA; PHI=Philadelphia, PA; PHX=Phoenix, AZ; POR=Portland, OR; STL=St Louis, MO (only has data through 2003); SDG=San Diego, CA; SEA=Seattle, WA; SFO=San Francisco, CA; and TRP=Tripler Army Medical Center, HI (does not provide sexual risk behavior data).
0%
50%
100%
'01 '02 '03 '04
% of Isolatesfrom MSM
BHM PHX
LBC LAX
ORA
SDG
SFO DEN
MIA
ATL
HON
TRP
CHI
NOR
BAL
DTR MIN
STL LVG
ALB
GRB
CIN
CLE
OKC
POR
PHI
DAL
SEA
STDs in Persons Entering Corrections Facilities
Sexually Transmitted Disease Surveillance 2004
Division of STD Prevention
Chlamydia — Positivity by age, juvenile corrections facilities, 2004
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
121.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
3.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
4.7
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
6.6
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
8.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
7.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
8.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
6.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12 8.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
11.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
16.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
16.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
16.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
16.6
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
14.3
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
14.3
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
15.9
Note: Percent positivity is presented from facilities reporting > 100 test results.
Chlamydia — Positivity by age, adult corrections facilities, 2004
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<2010.7
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
9.7
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
6.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
4.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
1.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
6.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20 19.8
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
14.8
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
10.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
7.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
5.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
9.6
Note: Percent positivity is presented from facilities reporting > 100 test results.
Gonorrhea — Positivity by age, juvenile corrections facilities, 2004
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
120.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
0.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
0.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.3
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
1.4
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12 7.6
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
4.3
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
5.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
6.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
5.8
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
5.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
4.6
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
5.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
19
18
17
16
15
14
13
12
5.5
Note: Percent positivity is presented from facilities reporting > 100 test results.
Gonorrhea — Positivity by age, adult corrections facilities, 2004
Note: Percent positivity is presented from facilities reporting > 100 test results.
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<203.8
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
4.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
2.8
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
3.0
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
4.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
3.7
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20 9.5
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
6.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
5.9
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
5.1
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
4.2
Men Positivity (%) Women
Age22.0 17.6 13.2 8.8 4.4 0.0 0.0 4.4 8.8 13.2 17.6 22.0
Total
>=35
30-34
25-29
20-24
<20
5.7
Chlamydia — Positivity among men and women in juvenile corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)Alabama 0 0 0 2 399 19.4 (15.4-23.4)Arizona 3 4,758 6.5 (6.1-8.3) 4 1,975 15.7 (3.7-21.6)California* 20 29,815 3.8 (1.2-12.9) 20 12,582 12.8 (6.3-19.9)Connecticut 1 507 3.2 1 163 11.0Delaware 1 1,137 5.5 1 290 11.0Georgia 2 1,751 17.9 (8.3-27.5) 2 5,417 17.6 (8.8-26.5)Illinois 2 4,752 6.6 (4.5-8.7) 1 662 24.3Indiana 1 890 6.6 1 292 18.5Kentucky 4 819 4.6 (1.4-5.8) 2 393 6.1 (2.4-9.9)Maryland 5 2,375 3.8 (1.0-7.8) 1 450 18.9Massachusetts 2 944 5.5 (5.2-5.8) 1 310 12.6Michigan 3 504 6.8 (5.6-12.7) 1 133 24.1Nebraska 1 970 8.8 1 336 17.3Nevada 1 120 4.2 0 0 0New Jersey 2 2,011 8.6 (5.9-11.2) 1 223 25.1New Mexico 1 551 6.7 0 0 0New York 8 11,265 6.2 (1.5-10.1) 5 1,059 17.6 (5.2-24.3)North Dakota 1 175 6.9 0 0 0Ohio 1 802 13.6 1 231 24.7Oklahoma 3 536 10.3 (4.3-10.6) 1 148 23.6Oregon 3 1,883 4.3 (3.0-10.7) 2 323 11.1 (5.9-16.3)Pennsylvania 2 227 5.3 (4.3-6.3) 0 0 0South Carolina 1 353 9.6 1 178 11.8Texas 3 3,937 6.2 (2.4-11.1) 4 1,719 14.3 (5.0-24.2)Utah 2 794 4.4 (4.4-4.4) 1 187 19.3Virginia 1 632 10.0 0 0 0Washington 5 1,381 5.9 (1.3-8.1) 2 246 12.4 (7.3-17.5)Wisconsin 2 746 4.1 (3.1-5.1) 0 0 0Total 81 74,635 5.8 (1.0-27.5) 56 27,716 14.0 (2.4-26.5)
Chlamydia — Positivity among men and women in adult corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)Arizona 2 348 16.6 (13.1-20.1) 2 3,460 10.3 (8.7-12.0)California* 6 4,571 5.3 (3.4-6.3) 5 7,518 8.2 (5.7-19.2)Colorado 2 269 15.5 (14.4-16.7) 1 156 11.5Delaware 0 0 0 1 564 3.7Hawaii 0 0 0 2 313 11.5 (7.1-16.0)Illinois 3 9,008 10.2 (2.8-19.0) 4 13,200 8.7 (5.7-10.4)Iowa 1 364 14.3 2 635 5.0 (3.0-7.0)Massachusetts 3 2,724 7.7 (6.5-10.8) 2 1,245 4.8 (4.7-4.9)
Michigan 1 105 15.2 1 109 8.3Missouri 1 1,422 7.9 2 314 4.9 (4.0-5.7)Montana 0 0 0 1 162 1.2Nebraska 4 2,096 9.3 (6.6-16.6) 1 253 13.8Nevada 1 144 23.6 1 128 22.7North Dakota 1 592 5.6 0 0 0Oregon 1 132 15.9 1 179 8.4Texas 1 426 11.5 2 1,936 6.8 (4.4-9.1)Utah 1 110 30.0 0 0 0Washington 0 0 0 1 1,258 5.0West Virginia 2 988 4.1 (0.7-7.6) 0 0 0Wisconsin 5 5,661 12.5 (3.2-19.1) 3 1,320 1.9 (1.8-7.2)Total 35 28,960 10.2 (0.7-30.0) 32 32,750 7.2 (1.2-22.7)
Gonorrhea — Positivity among men and women in juvenile corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)Alabama 0 0 0 2 399 11.4 (10.5-12.3)California* 7 20,284 0.7 (0.4-0.9) 8 5,909 4.0 (0.7-6.3)Connecticut 1 511 0 1 164 1.2Delaware 1 820 1.2 1 205 3.4Georgia 2 1,748 10.0 (1.7-18.2) 2 5,410 5.7 (2.8-8.7)Illinois 2 4,754 2.0 (1.5-2.4) 1 663 10.4Indiana 1 891 0 1 294 0Kentucky 4 817 0.9 (0.5-2.2) 2 394 3.9 (1.0-6.9)
Maryland 5 2,368 0.5 (0-1.1) 1 448 5.1Michigan 2 379 3.7 (3.5-3.8) 1 133 5.3Nebraska 1 970 0.7 1 336 2.7New Jersey 2 2,014 1.6 (0.8-2.3) 1 222 9.9New Mexico 1 551 0.4 0 0 0New York 5 9,934 0.8 (0.5-1.4) 3 559 3.9 (3.9-4.1)Ohio 1 802 4.1 1 231 11.3Oklahoma 3 536 0.5 (0-3.6) 1 145 16.6Pennsylvania 1 114 0 0 0 0South Carolina 1 353 3.7 1 178 3.9Texas 2 2,457 1.3 3 898 6.4 (6.0-8.2)Utah 0 0 0 1 181 4.4Washington 5 1,381 0.2 (0-1.8) 2 246 3.5 (1.8-5.1)Wisconsin 2 743 0.8 (0-1.7) 0 0 0Total 49 52,427 0.8 (0-18.2) 34 17,015 4.5 (0-16.6)
Gonorrhea — Positivity among men and women in adult corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)California* 6 4,275 1.4 (0-5.0) 5 7,518 5.0 (1.5-7.1)Colorado 2 270 2.5 (1.9-3.0) 1 157 4.5Delaware 0 0 0 1 402 1.2Hawaii 0 0 0 2 313 5.0 (2.4-7.6)Illinois 3 9,011 3.0 (2.6-4.2) 4 13,235 5.7 (1.0-8.4)Iowa 1 364 0.8 2 635 2.1 (0.2-3.9)Missouri 1 1,421 1.8 2 313 1.9 (1.7-2.2)
Montana 0 0 0 1 162 0Nebraska 4 2,096 1.1 (0-3.7) 1 253 4.7Nevada 1 144 13.2 1 128 7.0Texas 1 271 5.2 2 1,452 3.6 (1.8-5.3)Utah 1 110 13.6 0 0 0Washington 0 0 0 1 1,258 0.6West Virginia 2 994 31.6 (29.4-33.8) 0 0 0Wisconsin 5 5,660 3.5 (0-7.4) 3 1,320 0.9 (0-3.9)Total 27 24,616 2.6 (0-33.8) 26 27,146 3.0 (0-8.4)
Syphilis — Positivity among men and women in juvenile corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)California* 3 14,349 0.5 (0.3-0.5) 3 3,269 0.7 (0.6-0.8)Pennsylvania 1 4,723 0 1 827 0Texas 1 34,866 2.4 1 8,798 5.1Total 5 53,938 0.5 (0-2.4) 5 12,894 0.7 (0-5.1)
Syphilis — Positivity among men and women in adult corrections facilities, 2004
Note: The median positivity is presented from facilities reporting > 100 test results.*Includes Los Angeles and San Francisco.
State
Men Women
No. of Sites No. of Tests Median % Positivity (Range) No. of Sites No. of Tests Median % Positivity (Range)California* 1 1,262 4.3 1 595 3.9Maryland 1 14,984 2.2 1 3,583 10.0Massachusetts 1 3,442 1.3 1 528 1.9Mississippi 5 2,594 3.8 (2.6-5.9) 0 0 0North Carolina 7 16,997 2.9 (1.7-4.5) 7 3,611 8.3 (5.3-12.4)Ohio 3 30,131 0.6 (0.2-1.1) 3 5,012 1.4 (0-2.5)Pennsylvania 1 22,647 5.7 1 4,433 0.2
Tennessee 3 24,002 2.5 (2.0-4.2) 3 5,623 6.6 (1.2-19.0)Texas 1 63,768 3.3 1 19,210 7.3Wisconsin 1 1,252 1.8 1 711 5.2Total 24 181,079 2.7 (0.2-5.9) 19 43,306 5.3 (0-19.0)